Trial Profile
A PHASE II, MULTICENTER, UNCONTROLLED, OPEN STUDY IN PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY TO EVALUATE THE SAFETY AND EFFICACY OF A TREATMENT WITH THYMOSIN ALPHA 1 PLUS RIBAVIRIN.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2011
Price :
$35
*
At a glance
- Drugs Thymalfasin (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors sigma-tau SpA
- 26 Jul 2011 New trial record